Mirtazapine acutely inhibits basal and K super(+)-stimulated release of corticotropin-releasing hormone from the rat hypothalamus via a non-genomic mechanism

• Published in: Psychopharmacology 2005-02, Vol.178 (1), p.78-82
• Main Authors: Fabricio, Aline SC, Tringali, Giuseppe, Pozzoli, Giacomo, Navarra, Pierluigi
• Format: Article
• Language: English
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/s00213-004-1984-6

Rationale: Originally described as a pivotal mediator of acute neuroendocrine responses to stress, corticotropin-releasing hormone (CRH) is currently envisioned as a peptide neurotransmitter involved in the pathogenesis of anxiety and depressive disorders; it has been postulated that antidepressant drugs are clinically effective insofar as they are able to reduce central CRH production and release. Objectives and methods: In this study we used a well validated in vitro model, i.e. acute rat hypothalamic explants, to investigate the effects of the antidepressant mirtazapine on the production and release of CRH from the hypothalamus in short-term experiments. CRH release was assessed through the measurement of CRH immunoreactivity in the incubation medium. Results: We found that mirtazapine reduces in a concentration-dependent manner both basal and K super(+)-stimulated CRH release in 30-min and 60-min experiments. Mirtazapine had no effect on CRH mRNA expression in 1-h and 3-h experiments; the intra-hypothalamic levels of peptide were not reduced, and even tended to increase, with respect to controls. Conclusion: Mirtazapine reduces CRH release from CRH-containing neurons in the rat hypothalamus through a mechanism independent from the modulation of CRH gene expression and peptide production.